Activation of resident memory T cells for cancer immunotherapy
AssigneeRegents of the University of Minnesota
InventorsDavid B. Masopust, Jr., Vaiva D. Vezys
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating cancer by activating resident memory T cells using one or more antigenic peptides.
Claims18
An article of manufacture comprising:
- an adjuvant consisting essentially of an antigenic peptide from a first microorganism in a pharmaceutically acceptable carrier, wherein the first microorganism is CMV.
An article of manufacture comprising:
- an antigenic peptide from a first microorganism and an antigenic peptide from a second microorganism in a pharmaceutically acceptable carrier, wherein the first microorganism is CMV and the second microorganism is HPV.
A method of increasing the efficacy of immunotherapy in an individual, comprising administering an adjuvant to a solid tumor to activate resident memory T cells, wherein the adjuvant comprises at least one antigenic peptide from CMV, thereby increasing the efficacy of the immunotherapy in the individual.
A method of increasing the efficacy of immunotherapy in an individual, comprising administering an adjuvant to a solid tumor to activate resident memory T cells, wherein the adjuvant comprises at least one antigenic peptide from at least one pathogenic or infectious virus or bacteria against which the individual previously has developed an immune response, wherein the at least one virus or bacteria are selected from the group consisting of EBV, CMV, HPV, E. coli, H. pylori, and S. aureus,
- thereby increasing the efficacy of the immunotherapy in the individual.
Dependencies are inferred from the claim text.